阿托伐他汀钙对改善慢性硬膜下血肿出血量及神经功能的价值
|
摘要
目的探讨阿托伐他汀钙对改善慢性硬膜下血肿出血量及神经功能的价值。方法便利收集2017年3月—2018年4月该院100例慢性硬膜下血肿的患者,两组患者入院后给予营养神经、改善微循环、对症治疗。研究组在上述治疗上口服阿托伐他汀钙片。对比两组治疗前后慢性硬膜下血肿出血量;两组治疗前后神经功能;两组治疗前后体内炎症因子水平。结果研究组和对照组治疗前慢性硬膜下血肿出血量分别为[(74.25±16.71)m L、(75.16±17.44)mL],差异无统计学意义(t=0.355,P>0.05);研究组和对照组治疗后慢性硬膜下血肿出血量分别为[(23.26±7.23)m L、(53.15±8.96)mL],差异有统计学意义(t=6.332,P<0.05);研究组和对照组治疗前中国卒中量表分别为[(22.36±3.27)分、(22.09±4.02)分]差异无统计学意义(t=0.147,P>0.05);研究组和对照组治疗后中国卒中量表分别为[(12.85±1.98)分、(14.28±2.05)分]差异有统计学意义(t=5.287,P<0.05)。研究组手术后1 d及手术后3 dTNF-β及IL-4炎症因子指标均低于对照组,两组分别为[(39.62±5.14)ng/L、(56.24±15.34)ng/L、(5.42±1.18)ng/L、(12.16±1.87)ng/L]、[(59.14±5.22)ng/L、(7.96±3.37)ng/L、(65.97±16.02)ng/L、(23.64±2.26)ng/L],差异有统计学意义(P<0.05)。结论阿托伐他汀钙能够明显减少慢性硬膜下血肿患者的出血量,同时对提高神经功能有重要价值。
Objective To investigate the value of atorvastatin calcium in improving the amount of hemorrhage and neurological function in chronic subdural hematoma. Methods 100 patients with chronic subdural hematoma in our hospital from March 2017 to April 2018 were convenient selected and enrolled. The patients in the two groups were given nutritional nerves, improved microcirculation and symptomatic treatment after admission. The study group took oral atorvastatin calcium tablets on the above treatment. The amount of chronic subdural hematoma bleeding before and after treatment was compared between the two groups; as well as the neurological function before and after treatment; the levels of inflammatory factors in the two groups before and after treatment. Results The blood loss of chronic subdural hematoma in the study group and the control group was [(74.25±16.71)mL,(75.16±17.44)mL], the difference was not statistically significant(t=0.355, P>0.05). The study group and the control group after the treatment of the amount of post-chronic subdural hematoma was [(23.26±7.23)mL,(53.15±8.96)mL], the difference was statistically significant(t=6.332, P<0.05). The Chinese stroke scales of the study group and the control group were[(22.36±3.27)points, 22.09±4.02)points]. The difference was not statistically significant(t=0.147,P>0.05). The Chinese stroke scales of the study group and the control group were [(12.85 ±1.98)points,(14.28±2.05)points].The difference was statistically significant(t=5.287, P<0.05). The TNF-β and IL-4 inflammatory factors were lower in the study group than in the control group 1 day after surgery and 3 days after surgery. The two groups were [(39.62±5.14)ng/L,(56.24±15.34)ng/L,(5.42±1.18)ng/L,(12.16±1.87)ng/L], [(59.14±5.22)ng/L,(7.96±3.37)ng/L,(65.97±16.02)ng/L,(23.64±2.26)ng/L], the difference was statistically significant(P <0.05). Conclusion Atorvastatin calcium can significantly reduce the amount of bleeding in patients with chronic subdural hematoma, and it is of great value in improving nerve function.
Objective To investigate the value of atorvastatin calcium in improving the amount of hemorrhage and neurological function in chronic subdural hematoma. Methods 100 patients with chronic subdural hematoma in our hospital from March 2017 to April 2018 were convenient selected and enrolled. The patients in the two groups were given nutritional nerves, improved microcirculation and symptomatic treatment after admission. The study group took oral atorvastatin calcium tablets on the above treatment. The amount of chronic subdural hematoma bleeding before and after treatment was compared between the two groups; as well as the neurological function before and after treatment; the levels of inflammatory factors in the two groups before and after treatment. Results The blood loss of chronic subdural hematoma in the study group and the control group was [(74.25±16.71)mL,(75.16±17.44)mL], the difference was not statistically significant(t=0.355, P>0.05). The study group and the control group after the treatment of the amount of post-chronic subdural hematoma was [(23.26±7.23)mL,(53.15±8.96)mL], the difference was statistically significant(t=6.332, P<0.05). The Chinese stroke scales of the study group and the control group were[(22.36±3.27)points, 22.09±4.02)points]. The difference was not statistically significant(t=0.147,P>0.05). The Chinese stroke scales of the study group and the control group were [(12.85 ±1.98)points,(14.28±2.05)points].The difference was statistically significant(t=5.287, P<0.05). The TNF-β and IL-4 inflammatory factors were lower in the study group than in the control group 1 day after surgery and 3 days after surgery. The two groups were [(39.62±5.14)ng/L,(56.24±15.34)ng/L,(5.42±1.18)ng/L,(12.16±1.87)ng/L], [(59.14±5.22)ng/L,(7.96±3.37)ng/L,(65.97±16.02)ng/L,(23.64±2.26)ng/L], the difference was statistically significant(P <0.05). Conclusion Atorvastatin calcium can significantly reduce the amount of bleeding in patients with chronic subdural hematoma, and it is of great value in improving nerve function.
引文
[1]江庆炎,邱兵,肖刘福,等.醒脑静联合阿托伐他汀钙治疗慢性硬膜下血肿患者的临床疗效[J].中国医学创新,2018,15(30):17-21.
[2]张蕾,侯梅英,程刚,等.钻孔尿激酶注入联合阿托伐他汀钙对慢性硬膜下血肿患者术后神经功能及预后的临床观察[J]河北医药,2018,40(20):3137-3140.
[3]张亮亮,胡建刚.阿托伐他汀40mg日剂量治疗慢性硬膜下血肿的效果评价[J].海峡药学,2018,30(10):130-131.
[4]张春良,朱峰,陈雪飞,等.云南红药胶囊联合阿托伐他汀治疗术后复发性慢性硬膜下血肿疗效及对血清IL-6、VEGF、MMP-9、D-二聚体水平的影响[J].现代中西医结合杂志2018,27(28):3090-3093,3097.
[5]王琪鸿,任新海.锥颅引流术联合阿伐他汀治疗慢性硬膜下血肿的疗效分析[J].中国临床神经外科杂志,2018,23(9)620-621.
[6]李升.阿托伐他汀治疗术后复发慢性硬膜下血肿的临床疗效分析[J].临床医药文献电子杂志,2018,5(76):80-81.
[7]杨俊勇,王剑,聂君英.阿托伐他汀治疗慢性硬膜下血肿效果观察[J].临床合理用药杂志,2018,11(25):63-64.
[8]黎华清,陈志生,黎志洲.阿托伐他汀治疗慢性硬膜下血肿术后残血的效果[J].中国当代医药,2018,25(25):88-90.
[9]李新,钱兴龙,周明,等.阿托伐他汀联合钻颅冲洗外引流术治疗慢性硬膜下血肿临床疗效观察[J].中国社区医师2018,34(25):30,32.
[10]张垒,霍志会,李延辉,等.阿托伐他汀治疗慢性硬膜下血肿[J].中国现代药物应用,2018,12(16):109-110.
[2]张蕾,侯梅英,程刚,等.钻孔尿激酶注入联合阿托伐他汀钙对慢性硬膜下血肿患者术后神经功能及预后的临床观察[J]河北医药,2018,40(20):3137-3140.
[3]张亮亮,胡建刚.阿托伐他汀40mg日剂量治疗慢性硬膜下血肿的效果评价[J].海峡药学,2018,30(10):130-131.
[4]张春良,朱峰,陈雪飞,等.云南红药胶囊联合阿托伐他汀治疗术后复发性慢性硬膜下血肿疗效及对血清IL-6、VEGF、MMP-9、D-二聚体水平的影响[J].现代中西医结合杂志2018,27(28):3090-3093,3097.
[5]王琪鸿,任新海.锥颅引流术联合阿伐他汀治疗慢性硬膜下血肿的疗效分析[J].中国临床神经外科杂志,2018,23(9)620-621.
[6]李升.阿托伐他汀治疗术后复发慢性硬膜下血肿的临床疗效分析[J].临床医药文献电子杂志,2018,5(76):80-81.
[7]杨俊勇,王剑,聂君英.阿托伐他汀治疗慢性硬膜下血肿效果观察[J].临床合理用药杂志,2018,11(25):63-64.
[8]黎华清,陈志生,黎志洲.阿托伐他汀治疗慢性硬膜下血肿术后残血的效果[J].中国当代医药,2018,25(25):88-90.
[9]李新,钱兴龙,周明,等.阿托伐他汀联合钻颅冲洗外引流术治疗慢性硬膜下血肿临床疗效观察[J].中国社区医师2018,34(25):30,32.
[10]张垒,霍志会,李延辉,等.阿托伐他汀治疗慢性硬膜下血肿[J].中国现代药物应用,2018,12(16):109-110.